Testifenon, also known as testiphenon, testiphenone, chlorphenacyl dihydrotestosterone ester, or dihydrotestosterone 17β-(4-(bis(2-chloroethyl)amino)phenyl)acetate, is a synthetic anabolic–androgenic steroid (AAS) and a cytostatic antineoplastic agent (i.e., chemotherapeutic) that was never marketed.[1][2][3] It is an androgen ester – specifically, a chlorphenacyl nitrogen mustard ester of dihydrotestosterone (DHT) – and acts as a prodrug of these two components in the body.[1][2] The drug was developed in Russia as a tissue-selective cytostatic drug for the treatment of various cancers occurring in androgen receptor-expressing tissues that would have reduced side effects and toxicity relative to other chemotherapy drugs.[1][2]

See also

References

  1. ^ a b c Lagova ND, Sof'ina ZP, Shkodinskaia EN, Kurdiumova KN, Valueva IM (1988). "[The antineoplastic activity of testiphenon]". Voprosy Onkologii (in Russian). 34 (11): 1363–1368. PMID 3201773.
  2. ^ a b c Demidova NV, Serebryakova EA, Gasan-Guseinova ZG, Zimakova NI, Arzamastsev AP (November 1995). "Comparative pharmacokinetics of 3H-testiphenone and 3H-chlorophenacyl in peroral administration to mice". Pharmaceutical Chemistry Journal. 29 (11): 737–739. doi:10.1007/BF02331848. S2CID 31434647.
  3. ^ Oborotova NA, Smirnova ZS, Polozkova ZS, Baryshnikov AI (2002). "[Pharmacological aspects in the development of liposomal medicinal preparations for the internal injection of hydrophobic cytostatics]". Vestnik Rossiiskoi Akademii Meditsinskikh Nauk (in Russian) (1): 42–45. PMID 11882971.